Breaking News

Fibrocell, Intrexon in Degenerative Disease Alliance

January 4, 2016

Will combine fibroblast platform with Intrexon’s cellular engineering capabilities to generate cell-based therapeutics

Fibrocell Science and Intrexon have entered an Exclusive Channel Collaboration (ECC) for the development of genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions.

Fibrocell’s fibroblast platform will be combined with Intrexon’s cellular engineering capabilities to generate cell-based therapeutics that have been modified to express one or more proteins at sites of joint inflammation with the goal of helping to overcome the limitations of existing treatment options for chronic inflammatory and degenerative diseases of the joint.

Intrexon will receive a technology access fee of $10 million and reimbursement for R&D costs, as well as regulatory and commercial milestone payments of as much as $30 million and $22.5 million, respectively, and royalties on sales.

“The synergy of our versatile fibroblast platform with Intrexon’s genetic engineering is readily apparent through two product candidates, FCX-007 and FCX-013, which have generated encouraging preclinical data across difficult-to-treat indications,” said David Pernock, chairman and chief executive officer of Fibrocell. “We are excited by the expansion of our relationship with Intrexon and believe the power of our combined platforms will allow us to vie for leadership in this major therapeutic category and bring hope to patients and their families.”

“With present standards of care focused on limiting symptoms and slowing progression, optimal therapy for inflammatory, degenerative diseases of the joints represents a major unmet medical need and a significant commercial opportunity,” said Samuel Broder, M.D., senior vice president and head of Intrexon’s Health Sector.  “With Intrexon's Better DNA® suite of proprietary technologies, our engineered cell-based therapies may provide long-lasting effect while minimizing the repeated injections necessary with current treatments.”

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer